Statements (51)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
medication
|
| gptkbp:activeDuring |
gptkb:rosiglitazone
|
| gptkbp:availableIn |
brand name
generic version |
| gptkbp:clinicalTrials |
gptkb:Rosiglitazone_Evaluated_for_Cardiac_Outcomes_and_Regulation_of_Glycemia_in_Diabetes_(RECORD)
RECORD trial |
| gptkbp:contraindication |
stroke
liver disease pregnancy breastfeeding heart disease myocardial infarction bone fractures vision changes |
| gptkbp:date |
1999-05-25
|
| gptkbp:deployedTo |
2010-09-23
safety concerns cardiovascular risks |
| gptkbp:dosageForm |
tablet
|
| gptkbp:drugInterdiction |
highly protein-bound
metabolized by liver improves insulin sensitivity half-life of 3 to 4 hours increases glucose uptake reduces hepatic glucose production |
| gptkbp:formulation |
oral
|
| https://www.w3.org/2000/01/rdf-schema#label |
Avandia
|
| gptkbp:interactsWith |
NSAIDs
corticosteroids other antidiabetic agents thiazolidinediones |
| gptkbp:is_monitored_by |
cardiac function
liver function tests blood glucose levels |
| gptkbp:manufacturer |
gptkb:GlaxoSmithKline
|
| gptkbp:marketedAs |
gptkb:Canada
gptkb:European_Union gptkb:United_States |
| gptkbp:notableFeature |
insulin
Actos metformin sitagliptin |
| gptkbp:regulatoryCompliance |
restricted use
|
| gptkbp:sideEffect |
anemia
heart failure weight gain |
| gptkbp:skills |
8 mg
2 mg 4 mg |
| gptkbp:triggerType |
PPAR-gamma agonist
|
| gptkbp:usedFor |
type 2 diabetes
|